Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
266. |
ECCT/21/12/07 | GBT 132- Inclacumab Phase 3 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises. |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Videlis N Nduba 3. Fredrick Asirwa Chite Site(s) in Kenya 1. Strathmore University Medical Centre (Nairobi City county) 2. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) |
View |
267. |
ECCT/22/03/09 | GBT 132-Inclacumub PH3 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises. |
Principal Investigator(s) 1. Videlis N Nduba 2. Bernhards Ragama Ogutu 3. Fredrick Asirwa Chite Site(s) in Kenya 1. KEMRI Siaya Clinical Research Annex (Siaya county) 2. KEMRI/CRDR (Nairobi City county) 3. International Cancer Institute (ICI)-Eldoret (Uasin Gishu county) 4. Strathmore University Medical Centre (Nairobi City county) |
View |
268. |
ECCT/24/02/09 | pionERA This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy. |
Principal Investigator(s) 1. Dr Sitna Ali Site(s) in Kenya University of Nairobi -Institute of Tropical and Infectious Diseases |
View |
269. |
ECCT/21/07/02 | TALIOS A 3-ARM, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED, PHASE II STUDY OF RO7121661, A PD1-TIM3 BISPECIFIC ANTIBODY AND RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, COMPARED WITH NIVOLUMAB IN PARTICIPANTS WITH ADVANCED OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
View |
270. |
ECCT/23/11/01 | MPZ-MAL-01 A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed with Uncomplicated Plasmodium falciparum Malaria |
Principal Investigator(s) 1. Lucas Otieno Tina Site(s) in Kenya 1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 2. AHERO CLINICAL TRIALS UNIT (Kisumu county) 3. Kenya Medical Research Institute(KEMRI):Siaya Clinical Research Annex (Siaya county) |
View |